Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require a minimum of 6 hours of continuous IV sedation.~2. The ability to complete all PK sampling blood draws.~3. Age: subjects must fit into 1 of the following age ranges at screening:~   * Preterm neonates ≥28 weeks through \<36 weeks, gestational age; this would constitute treatment Group I.~  * Term neonates born at ≥36 weeks through ≤44 weeks gestational age; this would constitute treatment Group II.~4. Weight: subject's weight at the time of enrollment must be \>1000 g.~5. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).~Exclusion Criteria:~1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:~   * Diminished consciousness from increased intracranial pressure.~  * The presence of catastrophic brain injury or other severe mental disorders that would make responses to sedatives unpredictable and/or measurement of the N-PASS unreliable.~  * Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking (NMB) agents.~2. Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.~3. Heart rate \<120 bpm prior to the initiation of study drug.~4. Exposure to any investigational drug within 30 days prior to study drug administration.~5. Previous exposure to Dexmedetomidine (DEX) as part of an investigational study.~6. Maternal history of poly-substance drug abuse, based upon the presence of 1) an abnormal urine drug screen for cocaine, opiates and/or benzodiazepines; or 2) Investigator's judgment.~7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is expected to exceed its benefits.~8. Subjects who have a known allergy or contraindication to fentanyl, morphine, Midazolam, DEX, or other α-2 agonists.~9. Requirement for medications other than DEX, Midazolam, morphine, or fentanyl for sedation and pain control.~10. Screening alanine aminotransferase (ALT) levels \>115 U/L.

- Gender: ALL
- Minimum Age: 28 Weeks
- Maximum Age: 44 Weeks
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine 0.05 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
- Dexmedetomidine 0.1 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
- Dexmedetomidine 0.2 mcg/kg (Type: EXPERIMENTAL): Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).